Alltrna

Alltrna has received approval to initiate the first clinical trial of a tRNA therapeutic! It is more than a company milestone, it is a first step toward a different model for rare disease drug development, one built around shared genetic mutations instead of treating one disease at a time. Read the press release: alltrna.com/press/alltrna-… #tRNA #StopCodonDisease #rarediseases #clinicaltrials

This morning in Endpoints, Alltrna shared the news that a tRNA therapeutic is entering the clinic for the first time. One tRNA therapeutic could potentially treat patients across many diseases linked by the same genetic mutation. Scientists have understood the role of tRNA in protein translation for decades, but what did not exist was the ability to engineer, optimize, manufacture, and deliver tRNAs as medicines. Read Endpoints’ exclusive look at how this milestone could open the door to a more scalable path for developing medicines across rare genetic diseases. endpoints.news/first-clinical… #tRNA #StopCodonDisease #rarediseases #clinicaltrials

At Alltrna, we know progress is shaped by the people who inspire, support, and lead us. This Women’s History Month, our team is honoring the women who have made a lasting impact on our lives and work by sharing their stories and celebrating their influence.

As we prepare to advance our lead program into the clinic, we’re pleased to announce that Joanne Protano has been elevated to President and CFO and will guide Alltrna into its next phase as a clinical-stage company. Joanne has been instrumental in shaping Alltrna’s strategy and operations, and her deep knowledge of the business and commitment to our mission position the company strongly for this next chapter. @afzelius_lovisa, Alltrna Co-founder and Board Chair, will transition into the role of Executive Chair, working closely with Joanne and the Alltrna leadership team. Michelle Werner has made the decision to step down as CEO. We thank her for her leadership and the strong foundation she helped build for our tRNA platform. We are pleased she will continue with Alltrna as an advisor and member of the Board of Directors. We remain focused on advancing transformative tRNA medicines for patients. The momentum continues, and we’re energized for what’s ahead.

Understanding how specific gene variants shape PKU was the focus of our poster at the NPKUA 2026 Scientific Conference. Our Chief Medical Officer, Nerissa Kreher, MD, presented genotype–phenotype insights that help deepen our understanding of disease biology at the variant level. For families considering genetic testing, even after a diagnosis, this video may be helpful: rarediseases.org/why-should-i-g… Thank you to the @NPKUA_Info for convening this important meeting and for partnering with @RareDiseases to develop this educational video. #PKU #rarediseases #genetics #clinicalresearch #tRNA #StopCodonDisease

During #RareDiseaseWeek, we’re highlighting the role of genetic testing. For many families, this is an important next step, even after diagnosis, because knowing the specific gene variant may inform care and open access to clinical studies. Identifying the specific gene variant may: • Clarify the biological cause of disease • Inform ongoing care decisions • Highlight implications for relatives • Support access to clinical research and mutation-defined studies Learn more here: rarediseases.org/why-should-i-g… We are proud to have provided funding to support these educational videos, from the @RareDiseases, which were created in English and Spanish in partnership with the @NPKUA_Info and @OsmosisMed. #RareDiseaseWeek #rarediseases #genetictesting #clinicalresearch #tRNA #StopCodonDisease

What if rare disease drug development is at the same turning point oncology reached two decades ago? On the IDEA Collider podcast, Michelle Werner reflects on how oncology drug development was transformed once we began organizing around shared genetic drivers rather than tumor type. That shift led to targeted therapies, basket trials, and mutation-defined approvals that changed both clinical practice and patient outcomes. Approximately 10 percent of all genetic diseases are caused by premature termination codons. By engineering tRNA therapeutics to address this shared mutation, Alltrna is advancing a strategy designed to move beyond one drug, one disease and toward mutation-defined drug development across many rare genetic diseases. The question now is not about what tRNA biology can do. It is whether we are ready to build clinical and regulatory pathways that match it and expand what is possible for patients. Listen to the full conversation to hear Michelle’s perspective on leadership, urgency, and why this may be the inflection point for rare genetic diseases. youtu.be/wbQRAv0q9AQ

In recognition of the International Day of Women and Girls in Science, members of the Alltrna team joined @FlagshipPioneer for a conversation with Sally Kornbluth, President of MIT. Her candid reflections on leadership, career pivots, and the importance of staying curious were both relatable and energizing. What resonated most was the reminder that authenticity matters, because in science, progress is driven as much by people as it is by ideas. The courage to ask questions, to acknowledge uncertainty, and to grow alongside one another is part of how meaningful science gets done. #IDWGS #WomenInSTEM #tRNA #StopCodonDisease #rarediseases

Some conversations stay with you because of the people in the room. Thank you to eWIB Greater Boston for convening such a thoughtful fireside discussion, and to everyone who joined and contributed to a candid exchange on leadership, mentorship, and responsibility in biotech. We’re grateful to be part of a community that makes space for conversations like this. To learn more about eWIB, visit Women In Bio - Engage. Educate. Empower: womeninbio.org

Designing tRNA therapeutics starts with representing tRNAs as they operate, including their structural and chemical features, not just their sequence. That is why we are excited to collaborate with A*STAR – Agency for Science, Technology and Research to advance how chemically modified nucleotides on tRNA are represented in molecular simulations. Naturally occurring tRNAs rely on a rich landscape of chemical modifications on individual nucleotides to achieve their structure, stability, and function, and those same features are important when designing tRNAs as therapeutics. Conducted under A*STAR’s established collaboration with @FlagshipPioneer, our work together aims to broaden the technical toolkit that supports the design and evaluation of therapeutic tRNAs. #tRNA #StopCodonDisease #rarediseases #ASTAR

“We’re not looking at genes or proteins one at a time. We’re looking at the shared mutations across many different genes, and that changes how you think about scaling drug development for rare disease.” Hear Alltrna CEO Michelle Werner discuss how mutation defined strategies and basket trial thinking could expand access for patients who are often left out of traditional drug development models, and what this approach could unlock for the future of genetic medicines, on this special episode of The Genetics Podcast, recorded live at #JPM26 at @FlagshipPioneer studios.

Some of the most important leadership lessons don’t come from the lab or the boardroom. In early February, Alltrna will host an Executive Women In Bio (eWIB) Greater Boston fireside conversation featuring Alltrna’s Michelle Werner, moderated by Nerissa Kreher, MD, MBA, Chief Medical Officer at Alltrna. Michelle will reflect on the experiences that have shaped her leadership, from scientific rigor and mentorship to her personal perspective as the parent of a child with a rare disease, and how empathy and patient connection inform decision-making as biotech science moves toward patients. This invitation-only conversation brings together Executive (VP and above) members of WIB and select guests for a focused discussion on leadership and responsibility in biotech. To learn more about eWIB, vist Women In Bio - Engage. Educate. Empower: womeninbio.org

Scientific breakthroughs do not happen by accident. As @NoubarAfeyan's 2026 @FlagshipPioneer Annual Letter reminds us, they depend on sustained commitment to industry-changing science. This is especially important in rare diseases, where the need is greatest and the path is hardest. One #MiracleInTheMaking at Alltrna is the advancement of engineered tRNA therapeutics, a new modality built to address shared genetic mutations across many diseases, not developing one drug for one gene or one indication at a time. For patients who have historically been excluded from drug development because their diseases are too rare to pursue individually, this mutation-defined approach represents a life-saving path forward. Protecting and supporting the conditions that allow this kind of science to advance is essential to translating discovery into real options for families who have waited far too long. #FlagshipFounded #JPM26 #MiraclesInTheMaking

We’re looking forward to Wednesday’s live recording of The Genetics Podcast during #JPMWeek in San Francisco. The discussion will explore lessons learned as new RNA and gene editing approaches move closer to the clinic and what it takes to translate emerging genetic modalities into meaningful patient benefit. The live podcast with @patrick_j_short, co-founder and CEO of @SanoGenetics and hosted in partnership with @FlagshipPioneer will feature Alltrna CEO Michelle Werner and @TesseraTx CEO Michael Severino Space is limited, RSVP here: events.flagshippioneering.com/livethegenetic… #tRNA #StopCodonDisease #rarediseases #JPM26 #TheGeneticsPodcast

2025 was a year of momentum and big leaps at Alltrna. Guided by curiosity, courage, and a deep focus on patients, we advanced our first engineered tRNA therapeutic toward the clinic, shared data across scientific and patient communities, expanded our team with clinical and scientific leaders, and strengthened our connection to the communities we serve. Each step reflected our belief that patients deserve better and our commitment to boldly building a new future for those with Stop Codon Disease. As we look ahead to 2026, we’re energized by what we’ve achieved in such a short amount of time and are focused on taking the next meaningful steps in the clinic. #tRNA #StopCodonDisease #rarediseases #WeAreAlltrna

As the year comes to a close, we’re grateful for the way our team came together, giving back to our community and celebrating one another. Through our String of Giving donation drive supporting @c2cboston, Spoonfuls, and the @Gr8BosFoodBank, and moments of shared fun with a holiday sweater day and gift swap, our Alltrna team showed what it means to lead with generosity and purpose. Thank you to our team for an incredible year, and warm holiday wishes from all of us at Alltrna.

As Senior Legal Counsel at Alltrna, Nick Triano plays a critical role in our mission, protecting innovation, guiding our intellectual property strategy, and helping ensure that the groundbreaking work happening here can ultimately reach patients. In our latest Employee Spotlight, Nick shares how his career in patent law evolved into a passion for helping biotech innovators bring new therapies to life. He also talks about what excites him most about Alltrna’s mission, how our “We Are One Team” value shows up every day, and the rewarding challenge of helping advance a new therapeutic modality toward the clinic. See more at: alltrna.com/life-at-alltrna #WeAreAlltrna #tRNA #StopCodonDisease #EmployeeSpotlight